Fairvalue-Calculator Fairvalue-Calculator
EN DE

Invex Therapeutics Ltd (IXC) Fair Value & Analysis

Healthcare · AU · Market cap A$8.3M

PriceA$0.1100
Fair ValueA$0.0700
Upside-36.4%
Quality95/100
Evidence: Low Range A$0.0500 – A$0.0900

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Invex Therapeutics Ltd (IXC) currently trades at A$0.1100, while our model-based Fair Value estimate is A$0.0700 — implying the stock looks roughly 36.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company has a collaboration with Tessara Therapeutics. Invex Therapeutics Ltd was incorporated in 2019 and is based in Subiaco, Australia.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Invex Therapeutics Ltd (IXC) undervalued?
As of Jun 26, 2026, our model estimates a fair value of A$0.0700 versus a price of A$0.1100 — about −36% (overvalued). Model-based estimate, not financial advice.
What is the fair value of IXC?
Our 21-model fair value for Invex Therapeutics Ltd is A$0.0700 (as of Jun 26, 2026), built from audited fundamentals. The current price is A$0.1100.
What is the quality score of IXC?
Invex Therapeutics Ltd has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.